Cat. No.: HY-16107

Copy Link Print Information

BMS-303141

23 Cited Publications

Customer Review

Based on 23 publication(s) in Google Scholar

BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC₅₀ of 0.13 μM.

For research use only. We do not sell to patients.

Purity: 99.02%
CAS No.: 943962-47-8
Formula: C₁₉H₁₅Cl₂NO₄S
Molecular Weight:424.30

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

BMS-303141 Chemical Structure

CAS No.: 943962-47-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (23)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

BMS-303141 is a potent, cell-permeable ATP-citrate lyase (ACL) inhibitor with an IC₅₀ of 0.13 μM.

IC₅₀ & Target

IC50: 0.13 uM (ACL)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC₅₀	8 μM Compound: 9	Inhibition of total lipid synthesis HepG2 cells assessed as incorporation of [14C]total lipids after 6 hrs Inhibition of total lipid synthesis HepG2 cells assessed as incorporation of [14C]total lipids after 6 hrs	[PMID: 17383874]

In Vitro

In HepG2 cells, BMS-303141 shows inhibition of total lipid syntheses with an IC₅₀ of 8 μM. BMS-303141 shows no cytotoxicity up to 50 lM under a cell based Alamar Blue cytotoxicity assay, indicating the observed inhibition of lipid synthesis is not a result of compound-induced cytotoxicity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Chronic oral dosing of BMS-303141 in high-fat fed mice lowers approximate 20-30% plasma cholesterol and triglycerides, as well as 30-50% fasting plasma glucose. Chronic treatment with BMS-303141 shows a gradual inhibition of weight gain along with a reduction in adiposity without apparent changes in food intake. BMS-303141 shows an oral bioavailability of 55% but a relatively short half-life of 2.1 h^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 943962-47-8
Appearance Solid
Molecular Weight 424.30
Formula C₁₉H₁₅Cl₂NO₄S
Color White to off-white
SMILES

O=S(C1=CC(Cl)=CC(Cl)=C1O)(NC2=CC(C3=CC=CC=C3)=CC=C2OC)=O
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (23)

All 2D/3D Cell Culture and DifferentiationCell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Cell Metab

The enedioic acid analog 326E alleviates metabolic dysfunction-associated steatohepatitis via dual targeting at ACLY and PPARα. [Abstract]

2025 Oct 22:S1550-4131(25)00396-1. PMID: 41130202
Nat Cancer

A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling. [Abstract]

2023 Mar;4(3):344-364. PMID: 36732635

BMS-303141 purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2023 Mar;4(3):344-364. [Abstract]

3D spheroids growth upon genetic inhibition of either Cpt1a/CPT1A compared to cells infected with scramble as a control together with pharmacologic ALCY inhibition using BMS-303141 (20 μM, 5 days) in (d) 4T1 and (e) MCF10A H-RasV12 cells with or without extra palmitate and in the presence of the acetate as metabolic rescue (5 mM, 5 days).
Gastroenterology

Oncogenic Fatty Acid Metabolism Rewires Energy Supply Chain in Gastric Carcinogenesis. [Abstract]

2024 Jan 24:S0016-5085(24)00064-7. PMID: 38272100
Mol Cell

Lactate is an epigenetic metabolite that drives survival in model systems of glioblastoma. [Abstract]

2022 Aug 18;82(16):3061-3076.e6. PMID: 35948010
Nat Commun

MCT1-governed pyruvate metabolism is essential for antibody class-switch recombination through H3K27 acetylation. [Abstract]

2024 Jan 2;15(1):163. PMID: 38167945
Cell Death Dis

Fatty acid synthase-mediated lipid droplet formation enhances macrophage killing of Staphylococcus aureus. [Abstract]

2025 Oct 7;16(1):715. PMID: 41057302
Free Radic Biol Med

Sulforaphane impedes mitochondrial reprogramming and histone acetylation in polarizing M1 (LPS) macrophages. [Abstract]

2024 Mar:213:443-456. PMID: 38301976
Neoplasia

Metabolic regulation of histone acetylation by ACLY supports MDR1 expression in colorectal cancer and highlights a targetable vulnerability. [Abstract]

2026 Jul:77:101314. PMID: 42066427
Cell Chem Biol

AspSnFR: A genetically encoded biosensor for real-time monitoring of aspartate in live cells. [Abstract]

2024 May 20:S2451-9456(24)00179-X. PMID: 38806058
J Agric Food Chem

Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD. [Abstract]

2021 Aug 11;69(31):8714-8725. PMID: 34323067
J Bone Miner Res

Inhibition of ACLY Leads to Suppression of Osteoclast Differentiation and Function Via Regulation of Histone Acetylation. [Abstract]

2021 Oct;36(10):2065-2080. PMID: 34155695

BMS-303141 purchased from MedChemExpress. Usage Cited in: J Bone Miner Res. 2021 Oct;36(10):2065-2080. [Abstract]

Various concentrations of BMS-303141-treated (0, 6.25, 12.5, 25 μM) BMMs for different time periods (1, 3, 5 days). The cell viability and proliferation were assessed by CCK8 tests.

BMS-303141 purchased from MedChemExpress. Usage Cited in: J Bone Miner Res. 2021 Oct;36(10):2065-2080. [Abstract]

ANKL/M-CSF stimulated BMMs inthe presence of 25 μM BMS-303141 or control for indicated time periods (0, 1, 3, 5 days). Protein levels of indicated osteoclast markers were determined by Westernblot.
Chem Biol Interact

Discovery and characterization of novel ATP citrate lyase inhibitors from natural products by a luminescence-based assay. [Abstract]

2022 Nov 1:367:110199. PMID: 36174740
J Pathol

ZHX2 inhibits SREBP1c-mediated de novo lipogenesis in hepatocellular carcinoma via miR-24-3p. [Abstract]

2020 Dec;252(4):358-370. PMID: 32770671
Int J Mol Sci

Discovery of Flavonoids as Novel Inhibitors of ATP Citrate Lyase: Structure-Activity Relationship and Inhibition Profiles. [Abstract]

2022 Sep 15;23(18):10747. PMID: 36142671
Int J Mol Sci

2022, 23(18), 10747.
FASEB J

LPS stimulation stabilizes HIF-1α by enhancing HIF-1α acetylation via the PARP1-SIRT1 and ACLY-Tip60 pathways in macrophages. [Abstract]

2022 Jul;36(7):e22418. PMID: 35713568
FEBS Lett

ACSS2 involved in acetyl-CoA synthesis regulates skeletal muscle function. [Abstract]

2025 Oct;599(19):2817-2827. PMID: 40936396
Fitoterapia

Discovery and characterization of novel ATP citrate lyase inhibitors from Acanthopanax senticosus (Rupr. & Maxim.) Harms. [Abstract]

2024 Jun:175:105956. PMID: 38604261
Fitoterapia

Formyl phloroglucinol meroterpenoids from the leaves of Eucalyptus globulus subsp. maidenii and their ATP-citrate lyase inhibitory activities. [Abstract]

2024 Mar:173:105813. PMID: 38184174
bioRxiv

2026 Apr 20.
SSRN

2026 Mar 20.
NAR Mol Med

2026 Mar 24.
bioRxiv

2026 Feb 1.

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (58.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3568 mL

11.7841 mL

23.5682 mL

5 mM

0.4714 mL

2.3568 mL

4.7136 mL

10 mM

0.2357 mL

1.1784 mL

2.3568 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.5 mg/mL (5.89 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.89 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 2.5 mg/mL (5.89 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Animal Administration^[1]

Mice: Effect of BMS-303141 in high-fat fed mice is studied. There are a total of four groups in the study; mice on normal diet and high-fat diet controls, and two treated groups that are supplemented with BMS-303141 in their high-fat diet to an equivalent daily dose of 10 or 100 mg/kg. The study is continued for a total of 34 days. Food consumption and body weight gain are tracked along with weekly assessment of lipid and glucose plasma chemistries^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Li JJ, et al. 2-hydroxy-N-arylbenzenesulfonamides as ATP-citrate lyase inhibitors. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3208-11. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.3568 mL	11.7841 mL	23.5682 mL	58.9206 mL
	5 mM	0.4714 mL	2.3568 mL	4.7136 mL	11.7841 mL
	10 mM	0.2357 mL	1.1784 mL	2.3568 mL	5.8921 mL
	15 mM	0.1571 mL	0.7856 mL	1.5712 mL	3.9280 mL
	20 mM	0.1178 mL	0.5892 mL	1.1784 mL	2.9460 mL
	25 mM	0.0943 mL	0.4714 mL	0.9427 mL	2.3568 mL
	30 mM	0.0786 mL	0.3928 mL	0.7856 mL	1.9640 mL
	40 mM	0.0589 mL	0.2946 mL	0.5892 mL	1.4730 mL
	50 mM	0.0471 mL	0.2357 mL	0.4714 mL	1.1784 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

BMS-303141

Metabolism/Protease Compound Library

Anti-Cancer Metabolism Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) BMS-303141

Biological Activity

Chemical Information

Publications (23)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

BMS-303141

Metabolism/Protease Compound Library

Anti-Cancer Metabolism Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) BMS-303141

Biological Activity

Chemical Information

Publications (23)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

BMS-303141 Related Classifications

Cat. No.: HY-16107